Manufacturer Solutions
Cell and Gene Therapy
Moving healthcare forward
When healthcare advances, so must the processes to connect patients to the therapies they need. And because a rapidly changing cell and gene therapy industry requires an equally innovative partner, AmerisourceBergen is committed to delivering solutions that enable this connection.
Let’s build the future together.
For manufacturers
Distribution and Commercialization Services
From pre-clinical and commercial logistics to distribution and order to cash solutions, our experts can help you navigate the right options for your therapy. Our extensive reach has served patients for clinical trials and commercial distribution in the US, and in more than 50 countries worldwide.
For providers
Market Access and Reimbursement
We’ve helped commercially support 100% of the cell and gene therapies on the market today. Our experts offer market access, reimbursement and specific therapeutic area insights to help manufacturers understand the unique market landscape.
For patients
Impacting Patient Support
Hub services provide a holistic and comprehensive approach to ongoing patient support. We have the flexibility to design unique programs incorporating a full array of access, adherence and affordability solutions that meet patient needs.
Working together with manufacturers to identify and overcome barriers
Complete data solutions provide visibility to the patient journey
- Innovative patient access, affordability and adherence solutions unique to cell and gene therapies
- Expert guidance on market access, reimbursement and policy
- Complete logistics support, from pre-clinical through clinical trials to commercialization and post-launch solutions to ensure product quality standards are maintained
- Established relationships with thousands of healthcare providers optimizes the order to cash process and ease of prodcut access
Redefining moments that matter
"Innovative delivery systems, like cell and gene therapies, are requiring new levels of coordination and orchestration of multiple services, from scheduling and complex logistics to provider preparation and patient services, in order to ensure treatment success. We have an incredible opportunity to meet the growing challenges of our industry and be the 'go-to' global partner for manufactures in need of specialty solutions from clinical through commercial life stages."
Doug Cook
EVP and President, Global Commercialization Services and Animal Health
AmerisourceBergen
AmerisourceBergen
Our partnerships
Collaboration is essential to the creation of clinical and commercial scale logistics platforms. In order to support therapy developers, we have integrated systems and technology with a number of key partner organizations.
- Vineti
- Cytiva
- TrakCel
- Savsu Technologies
- Advanced Therapies Treatment Centres
Manufacturer Commercialization Strategy
AmerisourceBergen is the only pharmaceutical commercialization partner with the combination of proven solutions, diverse perspectives, and unmatched scale to make the most of scientific advances and change patient lives for the better. We build partnerships that unlock product potential and get medications to patients who need them.
Let's work together to envision new paths to healthier futures around the world.
Cell and Gene Therapy Insights
In the News
Xcenda's Ana Stojanovska Shares Insights on Market Access and Reimbursement for Cell and Gene Therapies with pharmaphorum
August, 4, 2020
Xcenda has worked with 100% of the cell and gene therapies launched in the US to date—and many of the pipeline assets currently in development. With this experience and expertise, Ana Stojanovska, Vice President of Commercial Consulting at Xcenda, shares perspectives on market access and reimbursement.
In The Realm of Cell and Gene Therapies World Courier Delivers
January 15, 2020
With the advent of cell and gene therapies, getting those treatments to the right patients at the right time requires both manufacturers and suppliers to offer the most reliable and timely logistics possible. With the FDA projecting it will likely approve as many as 10 to 20 cell and gene therapies every year by 2025, the stakes are being raised to get new treatments to market. As many of those new therapies are based on an individual’s own cells, patients themselves have become a key part of the new supply chain.
Unifying Cell Therapy Logistics and Manufacturing
December 5, 2019
Cell and gene therapies show promise as effective treatments, but there are some barriers to scaling them beyond the small numbers of patients they reach today. The supply chain and logistics for these advanced therapies are especially critical to ensure the right patient gets the right treatment at the right time. Collaboration is the key to solving challenges such as data management and process variability, as stakeholders work towards a common goal—getting these life-saving treatments to the people who need them.